Insider · CIK 0001548935

Elizabeth Mora

director

Files at MKSI (MKS INC), INGN (Inogen Inc), LMNR (Limoneira CO), BIRD (Allbirds, Inc.). First filing Dec 3, 2024, latest Sep 2, 2026.

Track record

Not enough history

Fewer than three past buys with six months of prices.

Median 6-month excess

after past buys, n = 0

Hit rate

past buys that beat the index over 6 months

Open-market trades

0 / 3

$0 bought, $131k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

MKSI: MKS INC

MKSIOct 9, 2026 · close 264.50

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

Score	Company	Value	Holdings	Price context	Filed
3Weak	MKSIsell10b5-1 MKS INC	$75k 300 shares	-2%	-	40 d ago
0Weak	MKSIsell10b5-1 MKS INC	$25k 300 shares	-2%	+41% from low-32% from high	Jun 3, 2025
8Weak	MKSIsell 210b5-1 MKS INC	$31k 275 shares	-2%	-	Dec 3, 2024

Transactions

Every row this insider has filed, newest first.

Date	Company	Transaction	Shares	Price	Value	Holdings after	Filed
Oct 1, 2026	BIRD Allbirds, Inc.	AGrant or award Class A Common Stock	+57,306	$3.49	$200k	57,306	7 d ago
Sep 1, 2026	MKSI MKS INC	SOpen-market sale Common Stock10b5-1	-300	$250.96	$75k	18,845	40 d ago
Jun 2, 2025	MKSI MKS INC	SOpen-market sale Common Stock10b5-1	-300	$81.78	$25k	19,563	Jun 3, 2025
May 14, 2025	INGN Inogen Inc	AGrant or award Common Stock	+30,612	$0.00	$0	79,180	May 16, 2025
May 12, 2025	MKSI MKS INC	AGrant or award Common Stock	+2,479	-	-	19,863	May 13, 2025
Apr 9, 2025	LMNR Limoneira CO	AGrant or award Common Stock	-5,090	$0.00	$0	17,535	Apr 11, 2025
Dec 2, 2024	MKSI MKS INC	SOpen-market sale Common Stock10b5-1	-275	$113.41	$31k	17,659	Dec 3, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.